<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00002463</url>
  </required_header>
  <id_info>
    <org_study_id>P88-006</org_study_id>
    <secondary_id>P30CA016672</secondary_id>
    <secondary_id>MDA-P-88006</secondary_id>
    <secondary_id>NCI-V89-0125</secondary_id>
    <secondary_id>CDR0000075917</secondary_id>
    <nct_id>NCT00002463</nct_id>
  </id_info>
  <brief_title>Combination Chemotherapy in Treating Children With Astrocytomas and Primitive Neuroectodermal Tumors</brief_title>
  <official_title>Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>M.D. Anderson Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>M.D. Anderson Cancer Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
      they stop growing or die. Combining more than one drug may kill more tumor cells.

      PURPOSE: Phase II trial to study the effectiveness of methotrexate, mechlorethamine,
      vincristine, procarbazine, and prednisone in treating children with astrocytomas or primitive
      neuroectodermal tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES: I. Determine the efficacy of high-dose methotrexate (HMTX) in combination with
      mechlorethamine, vincristine, prednisone, and procarbazine (MOPP) in infants or young
      children with primitive neuroectodermal tumors (PNET) (including medulloblastoma, anaplastic
      ependymoma, ependymoblastoma, or pineoblastoma) or high-grade astrocytoma. II. Determine
      whether the addition of HMTX to MOPP (MMOPP) improves the continuous complete response rate
      of MOPP alone and eliminates the need for salvage with radiotherapy in these patients. III.
      Determine the ability of MMOPP to provide neuroaxis prophylaxis or to treat spinal metastasis
      without radiotherapy in infants or young children with PNET. IV. Determine the toxicity of
      this regimen in terms of neurologic and neuropsychologic sequelae, growth, and development in
      these patients. V. Correlate the efficacy of this regimen with the histopathologic diagnosis
      of these patients. VI. Determine the optimum method for radiographic evaluation of spinal
      cord disease in patients with PNET. VII. Determine the utility of sequential spinal cord
      radiography as a means of monitoring PNET in these patients.

      OUTLINE: Patients undergo maximum tumor debulking. Patients who have undergone incomplete
      resection proceed to induction. Patients with a primary diagnosis of primitive
      neuroectodermal and pineal tumors or glioblastoma multiforme who have undergone total
      resection proceed to induction. Induction: Patients receive high dose methotrexate (HMTX) IV
      over 6 hours on day 1. Beginning 3 hours after completion of HMTX infusion, leucovorin
      calcium (CF) is administered IV over 30 minutes every 3 hours for 9 doses. Beginning 3 hours
      after completion of the last CF infusion, oral CF is administered every 6 hours for 8 doses.
      Patients receive a second HMTX infusion beginning 1 week after completion of the first HMTX
      infusion. Beginning 1 week after completion of the second HMTX infusion, patients receive
      mechlorethamine IV and vincristine IV on days 1 and 8, oral procarbazine and oral prednisone
      on days 1-10, and tapered doses of prednisone on days 11-13 (MOPP). Maintenance: Beginning 4
      weeks after initiating the first course of MOPP, patients receive HMTX on day 1 and MOPP
      beginning on day 4. Treatment continues every 31 days in the absence of disease progression
      or unacceptable toxicity. After 1 year or 14 doses of HMTX, whichever occurs first, HMTX is
      discontinued and treatment with MOPP alone continues every 4 weeks in the absence of disease
      progression or unacceptable toxicity. Treatment is discontinued after 2 years if the patient
      is in continuous complete remission.

      PROJECTED ACCRUAL: A total of 5-25 patients will be accrued for this study within 24-30
      months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>February 1989</start_date>
  <completion_date type="Actual">January 2008</completion_date>
  <primary_completion_date type="Actual">January 2007</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Patient with Overall Response</measure>
    <time_frame>Every 31 days</time_frame>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Brain and Central Nervous System Tumors</condition>
  <arm_group>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOPP Regimen</intervention_name>
    <description>Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP)</description>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin Calcium</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Mechlorethamine Hydrochloride</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Procarbazine Hydrochloride</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Vincristine Sulfate</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Conventional Surgery</intervention_name>
    <arm_group_label>Combination Chemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS: Histologically proven previously untreated (except surgically)
        primitive neuroectodermal tumors (including medulloblastoma, anaplastic ependymoma,
        ependymoblastoma, or pineoblastoma) or high-grade astrocytomas Low-grade astrocytomas or
        optic tract tumors that are incompletely resected and have a progressive course not
        amenable to further surgery may also be allowed Evaluable disease by MRI, CT scan, or CT
        myelography

        PATIENT CHARACTERISTICS: Age: Under 4 years Performance status: Not specified Life
        expectancy: At least 12 weeks Hematopoietic: Absolute granulocyte count greater than
        1,500/mm3 WBC greater than 4,000/mm3 Platelet count greater than 100,000/mm3 Hepatic:
        Bilirubin less than 1.5 mg/dL SGPT less than 90 IU/dL Renal: Creatinine clearance greater
        than 80 mL/min

        PRIOR CONCURRENT THERAPY: Biologic therapy: No concurrent immunotherapy Chemotherapy: No
        prior mechlorethamine, vincristine, procarbazine, and prednisone (MOPP) No prior high-dose
        methotrexate No other concurrent chemotherapy Endocrine therapy: Not specified
        Radiotherapy: No concurrent radiotherapy Surgery: See Disease Characteristics Other:
        Recovered from acute toxic effects of any prior therapy Must be on a tyramine-free diet
        during procarbazine administration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>3 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joann Ater, MD</last_name>
    <role>Study Chair</role>
    <affiliation>M.D. Anderson Cancer Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Texas - MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030-4009</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Ater J, Worth L, Bruner J, et al.: Young children treated with MOPP or methotrexate-MOP for medulloblastoma: identification of a subset of patients with good prognosis. [Abstract] Proceedings of the American Society of Clinical Oncology 14: A-1397, 1995.</citation>
  </results_reference>
  <results_reference>
    <citation>Ater JL, van Eys J, Yung WK, et al.: Response to methotrexate, mechlorethamine, vincristine, procarbazine, and prednizone (MMOPP) for brain tumors. [Abstract] Proceedings of the American Society of Clinical Oncology 10: A-370, 125, 1991.</citation>
  </results_reference>
  <verification_date>February 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 1, 1999</study_first_submitted>
  <study_first_submitted_qc>April 21, 2004</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2004</study_first_posted>
  <last_update_submitted>February 14, 2013</last_update_submitted>
  <last_update_submitted_qc>February 14, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 18, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>childhood infratentorial ependymoma</keyword>
  <keyword>childhood low-grade cerebral astrocytoma</keyword>
  <keyword>childhood low-grade cerebellar astrocytoma</keyword>
  <keyword>childhood supratentorial ependymoma</keyword>
  <keyword>childhood high-grade cerebral astrocytoma</keyword>
  <keyword>untreated childhood supratentorial primitive neuroectodermal tumor</keyword>
  <keyword>untreated childhood cerebellar astrocytoma</keyword>
  <keyword>untreated childhood medulloblastoma</keyword>
  <keyword>untreated childhood visual pathway and hypothalamic glioma</keyword>
  <keyword>newly diagnosed childhood ependymoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Astrocytoma</mesh_term>
    <mesh_term>Nervous System Neoplasms</mesh_term>
    <mesh_term>Central Nervous System Neoplasms</mesh_term>
    <mesh_term>Neuroectodermal Tumors</mesh_term>
    <mesh_term>Neuroectodermal Tumors, Primitive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Procarbazine</mesh_term>
    <mesh_term>Mechlorethamine</mesh_term>
    <mesh_term>Levoleucovorin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

